Group 1 - The core viewpoint of the news is the strategic collaboration between Huajian Medical and Renhe Pharmaceutical to establish the world's first OTC-focused Real World Asset (RWA) exchange in the United States, indicating a significant move in the RWA market [1][5] - The RWA market is gaining traction, with a projected total market value of $16 trillion by 2030, prompting numerous companies in both A-shares and Hong Kong stocks to enter the space [2] - Huajian Medical's "ETHK Global RWA Exchange" aims to create a comprehensive trading ecosystem for real-world assets, providing services such as asset selection, compliance issuance, and liquidity management [4][5] Group 2 - The RWA market is characterized by a growing number of companies, including Langxin Group and Xiexin Nengke, which are pioneering RWA practices in China through partnerships with Ant Group [2] - The infrastructure for RWA in China is still developing, with many companies facing challenges in finding comprehensive service providers for asset tokenization [4] - Huajian Medical's strategic acquisitions and compliance qualifications in overseas markets enhance its capability to provide end-to-end solutions for asset tokenization [8] Group 3 - Companies with high-quality, growth-potential assets are more likely to succeed in the RWA space, as exemplified by Renhe Pharmaceutical's strong brand portfolio and intellectual property assets [7] - The RWA industry chain involves various services, including asset verification, technology development, and liquidity provision, benefiting related financial institutions and service providers [7] - The recent market movements reflect a complex investor sentiment towards the RWA sector, with Renhe Pharmaceutical's stock rising by 5.49% and Huajian Medical's stock experiencing significant volatility [1]